Compensatory PI3-kinase Akt mTor activation regulates imatinib resistance development von BURCHERT, A, WANG, Y, CAI, D, VON BUBNOFF, N, PASCHKA, P, MÜLLER-BRÜSSELBACH, S, OTTMANN, O. G, DUYSTER, J, HOCHHAUS, A, NEUBAUER, A

Volltext

Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts von Ottmann, Oliver G, Wassmann, Barbara

Volltext

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease von Fiedler, Walter, Serve, Hubert, Döhner, Hartmut, Schwittay, Michael, Ottmann, Oliver G., O'Farrell, Anne-Marie, Bello, Carlo L., Allred, Randy, Manning, William C., Cherrington, Julie M., Louie, Sharianne G., Hong, Weiru, Brega, Nicoletta M., Massimini, Giorgio, Scigalla, Paul, Berdel, Wolfgang E., Hossfeld, Dieter K.

Volltext

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias von Ottmann, Oliver G., Druker, Brian J., Sawyers, Charles L., Goldman, John M., Reiffers, Jose, Silver, Richard T., Tura, Sante, Fischer, Thomas, Deininger, Michael W., Schiffer, Charles A., Baccarani, Michele, Gratwohl, Alois, Hochhaus, Andreas, Hoelzer, Dieter, Fernandes-Reese, Sofia, Gathmann, Insa, Capdeville, Renaud, O'Brien, Stephen G.

Volltext

Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia von Bug, Gesine, Ritter, Markus, Wassmann, Barbara, Schoch, Claudia, Heinzel, Thorsten, Schwarz, Kerstin, Romanski, Annette, Kramer, Oliver H., Kampfmann, Manuela, Hoelzer, Dieter, Neubauer, Andreas, Ruthardt, Martin, Ottmann, Oliver G.

Volltext

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study von Talpaz, Moshe, Silver, Richard T., Druker, Brian J., Goldman, John M., Gambacorti-Passerini, Carlo, Guilhot, Francois, Schiffer, Charles A., Fischer, Thomas, Deininger, Michael W.N., Lennard, Anne L., Hochhaus, Andreas, Ottmann, Oliver G., Gratwohl, Alois, Baccarani, Michele, Stone, Richard, Tura, Sante, Mahon, Francois-Xavier, Fernandes-Reese, Sofia, Gathmann, Insa, Capdeville, Renaud, Kantarjian, Hagop M., Sawyers, Charles L.

Volltext

Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells von BUG, Gesine, GÜL, Hilal, RUTHARDT, Martin, SCHWARZ, Kerstin, PFEIFER, Heike, KAMPFMANN, Manuela, XIAOMIN ZHENG, BEISSERT, Tim, BOEHRER, Simone, HOELZER, Dieter, OTTMANN, Oliver Gerhard

Volltext

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) von Wassmann, Barbara, Pfeifer, Heike, Stadler, Michael, Bornhaüser, Martin, Bug, Gesine, Scheuring, Urban J., Brück, Patrick, Stelljes, Matthias, Schwerdtfeger, Rainer, Basara, Nadezda, Perz, Jolanta, Bunjes, Donald, Ledderose, Georg, Mahlberg, Rolf, Binckebanck, Anja, Gschaidmeier, Harald, Hoelzer, Dieter, Ottmann, Oliver G.

Volltext

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia von Fiedler, Walter, Mesters, Rolf, Tinnefeld, Heike, Loges, Sonja, Staib, Peter, Dührsen, Ulrich, Flasshove, Michael, Ottmann, Oliver G., Jung, Wolfram, Cavalli, Franco, Kuse, Rolf, Thomalla, Joerg, Serve, Hubert, O’Farrell, Anne M., Jacobs, Mark, Brega, Nicoletta M., Scigalla, Paul, Hossfeld, Dieter K., Berdel, Wolfgang E.

Volltext

Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation von Hofmann, Wolf-K., Jones, Letetia C., Lemp, Nathan A., de Vos, Sven, Gschaidmeier, Harald, Hoelzer, Dieter, Ottmann, Oliver G., Koeffler, H. Phillip

Volltext

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia von Ottmann, Oliver G, Wassmann, Barbara

Volltext

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate von Kuroda, Junya, Kimura, Shinya, Segawa, Hidekazu, Kobayashi, Yutaka, Yoshikawa, Toshikazu, Urasaki, Yoshimasa, Ueda, Takanori, Enjo, Fumio, Tokuda, Harukuni, Ottmann, Oliver G., Maekawa, Taira

Volltext

Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia von Romanski, Annette, Bug, Gesine, Becker, Sven, Kampfmann, Manuela, Seifried, Erhard, Hoelzer, Dieter, Ottmann, Oliver G., Tonn, Torsten

Volltext

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia von Hofmann, Wolf-Karsten, Komor, Martina, Wassmann, Barbara, Jones, Letetia C., Gschaidmeier, Harald, Hoelzer, Dieter, Koeffler, H. Phillip, Ottmann, Oliver G.

Volltext

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia von Olavarria, E, Ottmann, O G, Deininger, M, Clark, R E, Bandini, G, Byrne, J, Lipton, J, Vitek, A, Michallet, M, Siegert, W, Ullmann, A, Wassmann, B, Niederwieser, D, Fischer, T

Volltext

Risk and Prognosis of Central Nervous System Leukemia in Patients with Philadelphia Chromosome-Positive Acute Leukemias Treated with Imatinib Mesylate von PFEIFER, Heike, WASSMANN, Barbara, LÜBBERT, Michael, LEIMER, Lothar, GSCHAIDMEIER, Harald, HOELZER, Dieter, OTTMANN, Oliver G, HOFMANN, Wolf-Karsten, KOMOR, Martina, SCHEURING, Urban, BRÜCK, Patrick, BINCKEBANCK, Anja, SCHLEYER, Eberhard, GÖKBUGET, Nicola, WOLFF, Thomas

Volltext

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C von Müller, M C, Gattermann, N, Lahaye, T, Deininger, M W N, Berndt, A, Fruehauf, S, Neubauer, A, Fischer, T, Hossfeld, D K, Schneller, F, Krause, S W, Nerl, C, Sayer, H G, Ottmann, O G, Waller, C, Aulitzky, W, Coutre, P le, Freund, M, Merx, K, Paschka, P, König, H, Kreil, S, Berger, U, Gschaidmeier, H, Hehlmann, R, Hochhaus, A

Volltext

Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry von KLEIN, S. A, DOBMEYER, J. M, DOBMEYER, T. S, PAPE, M, OTTMANN, O. G, HELM, E. B, HOELZER, D, ROSSOL, R

Volltext

Transcriptional Profiling of Human Hematopoiesis During In Vitro Lineage‐Specific Differentiation von Komor, Martina, Güller, Saskia, Baldus, Claudia D., de Vos, Sven, Hoelzer, Dieter, Ottmann, Oliver G., Hofmann, Wolf‐K.

Volltext

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) von WASSMANN, B, PFEIFER, H, SCHEURING, U, KLEIN, S. A, GÖKBUGET, N, BINCKEBANCK, A, MARTIN, H, GSCHAIDMEIER, H, HOELZER, D, OTTMANN, O. G

Volltext